Delcath Systems, Inc. (DCTH)
NASDAQ: DCTH · Real-Time Price · USD
12.79
-0.36 (-2.74%)
Mar 31, 2025, 1:11 PM EDT - Market open

Company Description

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.

The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.

It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe.

The company was founded in 1987 and is headquartered in New York, New York.

Delcath Systems, Inc.
Delcath Systems logo
Country United States
Founded 1988
Industry Medical Devices
Sector Healthcare
Employees 96
CEO Gerard Michel

Contact Details

Address:
566 Queensbury Avenue
New York, New York 12804
United States
Phone 212-489-2100
Website delcath.com

Stock Details

Ticker Symbol DCTH
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000872912
CUSIP Number 24661P807
ISIN Number US24661P8077
Employer ID 06-1245881
SIC Code 3841

Key Executives

Name Position
Gerard J. Michel MBA, MS Chief Executive Officer and Director
Sandra Pennell CPA Chief Financial and Accounting Officer
Dr. Martha S. Rook Ph.D. Chief Operating Officer
David Hoffman J.D. General Counsel, Corporate Secretary and Chief Compliance Officer
Dr. Johnny John M.D. Senior Vice President of Clinical Operations and Medical Affairs
Dr. Vojislav Vukovic M.D., M.Sc., Ph.D. Chief Medical Officer
Dr. Michael Brunner M.D. Senior Vice President of Interventional Oncology

Latest SEC Filings

Date Type Title
Mar 21, 2025 8-K Current Report
Mar 6, 2025 10-K Annual Report
Mar 6, 2025 8-K Current Report
Jan 27, 2025 SCHEDULE 13D/A Filing
Jan 13, 2025 8-K Current Report
Dec 30, 2024 8-K Current Report
Nov 14, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 14, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals